Formulation, characterisation and stabilisation of buccal films for paediatric drug delivery of omeprazole by Khan, Sajjad et al.
1 
Formulation, characterisation and stabilization  of buccal films for 1 
2 paediatric drug delivery of omeprazole 
Sajjad Khan
1#
, Joshua S. Boateng
1#
, John Mitchell
1
, Vivek Trivedi
1
3 
1
Department of Pharmaceutical, Chemical & Environmental Sciences, Faculty of Engineering 4 
and Science, University of Greenwich at Medway, Central Avenue, Chatham Maritime, ME4 5 
4TB, Kent, UK 6 
7 
8 
9 
* Corresponding author and request for reprint: (Joshua S Boateng)10 
Department of Pharmaceutical, Chemical & Environmental Sciences, Faculty of Engineering 11 
and Science, University of Greenwich at Medway, Central Avenue, Chatham Maritime, ME4 12 
4TB, Kent, UK 13 
Tel: + 44 (0) 208 331 8980, Fax: +44 (0) 208 331 9805 14 
E-mail: J.S.Boateng@gre.ac.uk; joshboat40@gmail.com 15 
16 
# Joint First Authors 17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
This is the Author’s Accepted Manuscript version of a paper published in AAPS 
PharmSciTech by Springer International Publishing on 6 January 2015. The final 
publication is available at Springer via http://dx.doi.org/10.1208/s12249-014-0268-7. 
2 
Abstract 30 
This study aimed to develop films for potential delivery of omeprazole (OME) via the buccal 31 
mucosa of paediatric patients. Films were prepared using hydroxypropylmethylcellulose 32 
(HPMC), methylcellulose (MC), sodium alginate (SA), carrageenan (CA) and metolose 33 
(MET) with polyethylene glycol (PEG 400) as plasticiser, OME (model drug) and L-arg 34 
(stabilizer). Gels (1% w/w) were prepared at 40°C using water and ethanol with PEG 400 (0 - 35 
1% w/w) and dried in an oven (40°C). Optimised formulations containing OME and L-arg 36 
(1:1, 1:2 and 1:3) were prepared to investigate the stabilization of the drug. Tensile properties 37 
(Texture analysis - TA), physical form (differential scanning calorimetry – DSC; X-ray 38 
diffraction – XRD; thermogravimetric analysis - TGA) and surface topography (scanning 39 
electron microscopy SEM) were investigated. Based on the TA results, SA and MET films 40 
were chosen for OME loading and stabilisation studies as they showed a good balance 41 
between flexibility and toughness. Plasticised MET films were uniform and smooth whilst 42 
unplasticised films demonstrated rough lumpy surfaces. SA films prepared from aqueous gels 43 
showed some lumps on the surface, whereas SA films prepared from ethanolic gels were 44 
smooth and uniform. Drug loaded gels showed that OME was unstable and therefore required 45 
addition of L-arg. The DSC and XRPD suggested molecular dispersion of drug within the 46 
polymeric matrix. Plasticised (0.5 % w/w PEG 400) MET films prepared from ethanolic 47 
(20% v/v) gels and containing OME: L-arg 1:2 showed the most ideal characteristics 48 
(transparency, ease of peeling and flexibility) and was selected for further investigation.  49 
50 
Keywords: Buccal drug delivery, Plasticiser, Oral films, Omeprazole, Paediatric51 
3 
 
Introduction 52 
Amongst all the established routes of drug administration, the oral route is perhaps the most 53 
preferred for both patients and healthcare providers compared to other routes such as 54 
injections. However, this route of administration has disadvantages including enzyme 55 
degradation within the gastrointestinal tract which prohibits oral administration of certain 56 
classes of drugs such as peptides and proteins.  Evidence has shown that the oral mucosa is 57 
relatively permeable with a rich supply of blood and shows a short recovery time after stress 58 
or damage. Further, it also lacks Langerhans cells which allow the oral cavity to be tolerant of 59 
any potential allergens (1).  Drug administration within the oral mucosa is generally classified 60 
into sublingual and buccal delivery. Among all the trans-mucosal routes, the buccal mucosa 61 
has excellent accessibility, an expanse of smooth muscle and relatively immobile mucosa, 62 
hence suitable for the administration of retentive dosage forms (2-3). Direct access to the 63 
systemic circulation through the internal jugular vein bypasses hepatic first pass metabolism 64 
leading to relatively high bioavailability compared to the GI tract. Additionally, the buccal 65 
mucosa has a high surface area (50.2 cm
2
) and a thin membrane (500–600 μm) which can 66 
contribute to rapid and extensive drug absorption (4).  67 
 68 
Oral drug delivery systems have always been an important means of drug administration; 69 
however, many paediatric patients resist solid dosage forms such as tablets due to the bitter 70 
taste and fear of choking. Though sweetened liquid formulations are commonly used, they 71 
present many challenges including bitter after taste, unpleasant flavours, short half lives once 72 
opened and generally bulky to handle and store. Oral thin films offer easy administration and 73 
handling, rapid disintegration and dissolution, bypass first-pass metabolism, enhanced 74 
stability and taste masking for bitter drugs, local and systematic drug delivery, rapid onset of 75 
action and no trained or professional person is required for paediatric administration (5). Due 76 
to the numerous advantages of buccal dosage forms, various technologies have been explored 77 
to manufacture oral films on a large scale as an alternative to traditional dosage forms such as 78 
tablets and capsules (6). 79 
 80 
Numerous buccal delivery systems in the form of tablets, liquids and semi-solids have been 81 
reported in the past decades yet only a limited number of these have reached the market (7). 82 
The necessity of recurrent dosing might possibly arise due to the flushing activity of saliva, 83 
chewing and the ingestion of food materials which results in the rapid expulsion of drugs. 84 
Moreover, the drugs in the saliva may be unevenly distributed, which might consequently 85 
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lead to lower amounts being absorbed by the mucosal tissues directly into the systemic 86 
circulation. Furthermore, the likely displacement of the formulation from the buccal area by 87 
tongue movements serves as an additional challenge (8). The above notwithstanding, the 88 
buccal mucosal route is still considered a practical route to deliver a variety of active 89 
ingredients.  90 
 91 
Hydrophilic polymers incorporating several hydrogen bonding groups make the formulation 92 
of bioadhesive buccal formulations feasible. Modified forms of such hydrogel polymers with 93 
better bioadhesivity create second-generation mucosal dosage forms (9). In the present study 94 
we report on the development of solvent cast films for buccal delivery in paediatric patients 95 
using various hydrogel polymers generally regarded as safe (GRAS) and used in mucosal 96 
formulations (10-13) including HPMC, MC, CA, MET, SA, plasticiser (PEG 400), OME 97 
(model drug) and L-arg (to stabilise OME). Various parameters such as drying times and 98 
temperatures, casting solvents as well as polymer and plasticiser concentrations were 99 
investigated and the films subsequently characterised as part of the development and 100 
optimisation.  101 
 102 
Methods 103 
Materials 104 
 105 
Carrageenan (CA) and sodium alginate (SA) were gifts from FMC Bio-Polymer and 106 
originally sourced from Cork (Republic of Ireland). Metolose (MET) was obtained from Shin 107 
Etsu (Stevenage, Hertfordshire). Hydroxypropylmethylcellulose (HPMC), methylcellulose 108 
(MC), polyethylene glycol (PEG 400), L-arginine (L-arg) were obtained from Sigma-Aldrich 109 
(Gillingham, UK). Ethanol was purchased from Fisher Scientific (Loughborough, UK). 110 
Omeprazole (OME) obtained from TCI (Tokyo, Japan). 111 
 112 
Formulation (gel and film) development 113 
Aqueous and ethanolic gels of the different polymers were prepared prior to film casting. 114 
The aqueous gels were formulated by adding the required weight of polymers to the relevant 115 
solvent (deionised water) at laboratory temperature (22°C) to obtain 1% w/w gels. Following 116 
complete hydration (dissolution), the polymeric gels were heated to 40°C. Based on the total 117 
weight of polymers, various amounts of the plasticiser (PEG) were added to obtain different 118 
concentrations (0.00%, 0.10%, 0.25%, 0.50%, 0.75% and 1.00% w/w) in the final gels 119 
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prepared. The resultant gels were left on a water bath with regulated temperature of 40°C 120 
(except for CAR which was prepared at 70°C) and stirring continued for 30 min to achieve a 121 
homogeneous dispersion. For ethanolic gels, the appropriate volume of ethanol (10% and 122 
20% v/v) was added to yield the 1% w/w total concentration. The solution was left to cool to 123 
room temperature and stirred again for 30 min. The final solutions were left to stand 124 
overnight to remove entrapped air bubbles. After removal of the air bubbles, 20 g of each gel 125 
was poured into Petri dishes (86 mm diameter) and kept in a pre-heated oven at 60°C for 24 126 
h. The dried films were then carefully peeled off from the Petri dish, images captured using a 127 
digital camera and transferred into poly bags and placed in a desiccator over silica gel at 128 
room temperature until required. 129 
 130 
Formulation development and optimization of OME loaded films 131 
The main purpose for the development and optimization was to determine the optimised 132 
amount of the drug that could be incorporated into the solvent cast film whilst still 133 
maintaining the ideal physical characteristics in terms of flexibility, homogeneity and 134 
transparency (14). The OME-loaded films were obtained by initially preparing MET gels as 135 
previously described above. However, the drug was added to the appropriate volume of water 136 
/ ethanol to form an OME solution as can be shown in table 1. The polymer was then added 137 
slowly to the vigorously stirred drug solution at room temperature to obtain the drug loaded 138 
gels. The resulting gels were covered with parafilm as above, and left overnight to allow air 139 
bubbles to escape, and then 20 g was poured into Petri dishes and dried at 40°C (15).  140 
 141 
Table 1- Drug loaded MET gels formulated using different solvent systems and containing 142 
different amounts of PEG 400 (0 and 0.5% w/w). 143 
Solvent 
Systems 
Water: ethanol(ml) 
 
MET (g) 
 
 
OME (g) 
 
Plasticizers (g) 
0% 0.5% 
Water 50:0 (1:0) 0.50 0.10 0.00 0.25 
10% v/v ethanol 45:5 (9:1) 0.50 0.10 0.00 0.25 
20% v/v ethanol 40:10 (4:1) 0.50 0.10 0.00 0.25 
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 144 
Stabilization of OME in drug loaded MET films using L-arg 145 
Due to the breakdown of OME following gel formation, L-arg was used as a stabilising agent 146 
to prevent drug degradation. Table 2 shows the details for the different ratios of OME and L-147 
arg in the gel formulations which were investigated. This step was performed by using 148 
different amounts of L-arg within the gel whilst keeping the original OME concentration 149 
(0.10% w/w) constant. The gels were prepared as above with L-arg and OME dissolved in the 150 
solvent before addition of MET and PEG 400. 151 
 152 
Table 2 – Different OME: L-arg ratios in the MET gel formulations for preparing both 153 
unplasticised and plasticised films (0 and 0.5% w/w (PEG 400 respectively)  154 
Solvent 
Systems 
Water: 
ethanol 
(ml) 
MET  
(g) 
 
Drug (g) 
OME 
OME : L-arg (g) 
Plasticizers 
(g) 
1:1 1:2 1:3 0% 50% 
Water 50:0 (1:0) 0.50 0.10 0.10 0.20 0.30 0.00 0.25 
10% v/v 
ethanol 
45:5 (9:1) 0.50 0.10 0.10 0.20 0.30 0.00 0.25 
20% v/v 
ethanol 
40:10 (4:1) 0.50 0.10 0.10 0.20 0.30 0.00 0.25 
 155 
Characterization of the films 156 
 157 
Tensile characterisation by texture analysis 158 
Texture analysis (TA) was used to measure tensile properties. A texture analyser (HD plus, 159 
Stable Micro System, Surrey, UK) equipped with 5 kg load cell was used. Thickness and 160 
width of the films were measured and stress and strain values were calculated based on these 161 
values. Data evaluation was performed by texture exponent-32 software program. The films 162 
free from any physical defects, with the average thickness of (0.07 ± 0.01 mm) were selected 163 
for testing. The films were cut into dumb-bell shaped strips and fixed between two tensile 164 
grips positioned 30 mm apart and stretched at a test speed of 1.0 mm/s to break point. The 165 
tensile strength (brittleness of the film), elastic modulus (rigidity) and percentage elongation 166 
(flexibility and elasticity) were determined using equations 1, 2 and 3. Each testing was 167 
carried out in triplicate (n = 3) 168 
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Scanning electron microscopy (SEM) 177 
SEM was used to investigate the surface morphology of the films and to check for film 178 
uniformity and the presence of any cracks. The films were analysed using a Hitachi Triple 179 
detector CFE-SEM SU8030, (Roland Schmidt, Hitachi High-Technologies Europe GmbH) 180 
scanning electron microscope. Films were mounted onto 12 mm aluminium pin stubs (G301, 181 
Agar Scientific) with double-sided adhesive carbon tapes (G3347N, Agar scientific) and 182 
chrome coated (Sputter Coater S150B, 15 nm thickness). The coated films were analysed at 2 183 
kV accelerating voltage. 184 
 185 
Differential scanning calorimetry (DSC) 186 
DSC was used to characterise the thermal behaviour of selected optimised MET and SA films 187 
and pure materials to investigate changes in their properties with introduction of PEG and 188 
drug within the films. Analysis of the films and starting materials were carried out on a 189 
Q2000 (TA Instruments) calorimeter. About 2.5 mg of each sample was placed into 190 
hermetically sealed Tzero aluminium pans with a pin hole in the lid and heated from -40°C to 191 
180°C at a heating rate of 10°C/min under constant purge of nitrogen (100 ml/min).  192 
 193 
Thermogravimetric analysis (TGA) 194 
TGA studies were performed using a Q5000 (TA instrument) thermogravimetric analyser. 195 
About 2.5 mg of sample (films and starting materials - MET and SA) was placed into 196 
hermetically sealed Tzero aluminium pans with a pin hole in the lid. Samples were heated 197 
under nitrogen atmosphere at a flow rate of 25 ml/min from ambient temperature to 600°C at 198 
a heating rate of 2°C/min. 199 
 200 
8 
 
X-ray diffraction (XRD) 201 
XRD was used to investigate the physical form (crystalline or amorphous) of the selected 202 
optimised films and starting materials (MET, SA and PEG). XRD patterns of films and 203 
starting materials were obtained with a DIFFRAC plus instrument (Bruker Coventry, UK) 204 
equipped with an XRD commander programme. A Goebel mirror was used as mono-205 
chromator which produced a focused monochromatic CuKα1&2 primary beam (λ=1.54184 Å) 206 
with exit slits of 0.6 mm and a Lynx eye detector for performing the experiment. The 207 
operating conditions during the experiment were 40 kV and 40 mA. Film samples were 208 
prepared by cutting into 2 cm
2 
square strips, mounted on the sample cell and scanned between 209 
2 theta of 0° to 70° and counting time of 0.1 second step size. 210 
 211 
Results and Discussion  212 
 213 
Formulation development and optimisation 214 
Omeprazole is an ideal candidate for buccal drug delivery using polymeric films as the 215 
delivery system, as it degrades readily in acidic medium and undergoes first pass metabolism 216 
(16). The polymers used in this study were chosen because of their hydrophilic nature. 217 
Stirring was applied during gel formulation to prevent formation of lumps which could occur 218 
through incomplete hydration especially for polymers with high viscosity. The heat (40°C or 219 
70°C) reduced the viscosity of the final gels and helped to facilitate the escape of entrapped 220 
air bubbles caused by stirring and also allowed ease of pouring into the casting Petri dishes. 221 
Ethanol was used as solvent in addition to deionised water because some polymers/ drugs are 222 
more soluble in ethanol than water and the former also helped to increase the rate of drying. 223 
The removal of the air bubbles entrapped inside the gel was essential to avoid any empty 224 
gaps, which could lead to non-uniform distribution of various film components. The drying 225 
process for unplasticised gels was shorter (12 h) compared to plasticised gels (18-24 h) due to 226 
the known water affinity of most plasticisers (17). 227 
 228 
Visual evaluation of films 229 
The MET and SA films were transparent, uniform and easy to peel from the Petri dishes. 230 
However, though HPMC, MC and CA films were transparent, they were not uniform due to 231 
the presence of air bubbles during drying, and were difficult to peel off without damaging the 232 
films (figure 1). Further, HPMC and MC films showed excessive elasticity at high 233 
concentrations of PEG which made them sticky. As a result, films prepared using CAR, 234 
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HPMC and MC was discontinued from further investigations and only MET and SA films 235 
were taken forward for further development and drug loading.  236 
 237 
Further development of MET and SA films, during the preliminary experiments, involved 238 
preparing films with and without plasticiser. The main purpose of using plasticiser is to 239 
provide flexibility and to overcome the brittleness in films. Un-plasticised MET and SA films 240 
were brittle whilst films plasticised with PEG showed reduced brittleness and desirable 241 
flexibility (18). Optimum plasticiser concentration(s) for further formulation development 242 
was however, investigated by using texture analysis to determine film tensile properties 243 
which provided more reliable data for accurate evaluation.  244 
 245 
Tensile properties of films 246 
Generally, soft and weak polymers have low tensile strength, low elastic (Young’s) modulus 247 
and low percent elongation at break. On the other hand soft and strong polymers display 248 
acceptable strength, low elastic modulus and high percent elongation at break (17). The films 249 
showed significant differences in the tensile strength (brittleness) based on the PEG 250 
concentration. The initial linear portion of the stress-strain curve was used to estimate the 251 
elastic modulus and tensile strength (19). The effects of PEG concentration on the tensile 252 
strength values of the MET and SA films are shown in figure 2a and 2b respectively. The 253 
percent elongation at break point of MET gradually increased with increased concentration of 254 
PEG. It has been suggested that the average percent elongation at break point should ideally 255 
be between 30-60% (17) which indicates a good balance between flexibility and elasticity. 256 
MET films prepared from gels containing 0.5 and 0.75 % w/w of PEG satisfied these criteria. 257 
MET films prepared from aqueous and ethanolic (water, 10% v/v and 20% v/v of EtOH) gels 258 
containing 0.50% w/w PEG, showed % elongation of break values between 27-57%. 259 
Unplasticised films prepared using water as the casting solvent showed a very low percent 260 
elongation at break (figure 2 a) whilst films obtained from EtOH (10% v/v and 20% v/v) gels 261 
showed a showed significantly higher values of percent elongation. There was also a general 262 
increase in percent elongation with increasing concentration of PEG for all films. At the 263 
concentration of 0.75% w/w of PEG, all the films showed elongation at break point of 55-264 
58% which was deemed high. Compared to MET films, SA films demonstrated low values in 265 
the overall % in elongation break. 266 
Generally, plasticisers such as PEG in the system increase the free volume between the 267 
polymeric chains and allow them to slide past each other and subsequently produced 268 
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appropriate flexibility and consequent decrease in tensile strength and elastic modulus (20). 269 
Based on these observations all subsequent gels for drug loading were prepared using only 270 
MET at two concentrations (0.00 % and 0.50 % w/w (original gel) of PEG, with the 271 
unplasticised films being used as a control.  272 
 273 
Physical evaluation of drug loaded films 274 
When OME is added to water, it dissolves quickly to produce a clear solution. After adding 275 
polymer and desired amount of plasticiser in solution for gel formation, the stability of OME 276 
plays a vital role in the overall stability of the gel (21). However, it was observed that OME 277 
degraded within 20 minutes and changed the colour of the gel to red as can be seen in figure 278 
3a. This resulted in a completely opaque and brown coloured film as shown in figure 3b. 279 
OME can only be stable in alkaline solution with pH of 8 and stability can be achieved in two 280 
main ways: (i) introducing cyclo-dextrin or (ii) L-arg to the drug loaded gel. However, 281 
because of the toxicity of cyclo-dextrin for paediatric patients, use of L-arg was the preferred 282 
option (22). To determine the optimum concentration of L-arg required to stabilize the drug 283 
and determine its effect on MET film properties, different amounts relative to the drug were 284 
added to the original gels before drying as shown in table 2 above. Blank MET films showed 285 
complete transparency similar to that shown in figure 1; whereas drug loaded films 286 
containing L-arg were slightly cream in colour as shown in figure 3c.  287 
 288 
Generally, plasicised drug loaded films containing OME and L-arg (1:1; 1:2 and 1:3) showed 289 
a significant difference in their visual appearance compared to unplasticised films with the 290 
former showing better transparency and uniformity. Another difference observed between the 291 
different formulations was that the films prepared from aqueous only gels, were difficult to 292 
peel off from the Petri dish due to their thin nature. Further, the distribution of OME and L-293 
arg was more uniform in the films prepared from the ethanolic gels (10% and 20% v/v 294 
EtOH). It was therefore concluded that films prepared from ethanolic gels (EtOH 20%) were 295 
the most transparent and uniform which could be due to complete molecular dispersion of 296 
drug (OME) and L-arg within the polymeric matrix. 297 
 298 
Based on the visual observation and the expected characteristics for an ideal film in terms of 299 
flexibility, uniformity and transparency, films prepared from ethanolic gels (20% v/v EtOH) 300 
containing 1:2 ratio of OME: Larg and 0.5% w/w PEG400 was the most appropriate for 301 
further investigations. It was also obvious that the addition of L-arg helped to stabilise the 302 
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drug within the films as can be seen by comparing figures 3b and 3c, with the latter showing 303 
desired homogeneity, transparency and uniform drug distribution. Figueiras et al (23) 304 
suggested that when combined together, the H atom of the L-arg was observed to be in closer 305 
proximity to the nitrogen atom of OME. They also observed that the distance between the H 306 
(L-arg) and the N (OME) is relatively small which increases the chances of formation of 307 
hydrogen bonds between the two compounds. 308 
   309 
Scanning electron microscopy (SEM) 310 
SEM images of the MET films cast from gels prepared with different solvents (water, 10% 311 
EtOH and 20% EtOH) with or without PEG (0.50% w/w) are shown in figure 4a. The 312 
microscopic appearance of all MET films, showed continuous sheets with relatively smooth 313 
and homogeneous surfaces and suggest that all the components were uniformly mixed during 314 
gel formation. The plasticised films showed smooth and homogeneous surfaces whilst 315 
unplasticised films showed rougher surfaces with some lumps. The surface topography of the 316 
SA films was dependent on the solvent used during gel preparation. Films prepared from 317 
aqueous gels showed considerably rougher surfaces than films prepared using 10% EtOH, 318 
which in turn showed uneven surfaces than films prepared using 20% EtOH as shown in 319 
figure 4b. This could be related to the more rapid drying of ethanolic gels during film 320 
formation. Such differences in surface topography could influence the uniformity of the 321 
films, because any pores or lumps in the film could affect the subsequent functional 322 
performance of different formulations with respect to hydration capacity/swelling studies, 323 
mucoadhesion and drug release characteristics. 324 
 325 
Differential scanning calorimetry (DSC) 326 
The thermogram for pure MET and SA can be seen in figure 5a, showing a broad 327 
endothermic peak at between 80 - 95°C, caused by evaporation of water and no definite melt 328 
or glass transition peaks. In general the thermograms of the films shown in figure 5b were 329 
similar to the pure MET powder. Figure 5b further shows the different MET films [aqueous 330 
and ethanolic (10% and 20% EtOH)] which were prepared using different percentages of 331 
PEG 400. All the films can be characterized as amorphous, as only the broad endothermic 332 
peak can be observed between 40 and 100°C which is attributed to water loss. 333 
 334 
The DSC thermograms for pure OME, L-arg and drug loaded MET OME 1: 2 L-arg 335 
0.50%PEG EtOH 20% films are shown in figure 5c. It can be observed that OME has a 336 
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melting point at 158°C and L-arg at 100°C and broad endothermic peak which can be seen at 337 
80°C for the drug (L-arg) loaded film representing water loss and a complete absence of the 338 
melt peaks for both OME and L-arg. This suggests amorphous drug formation or molecular 339 
dispersion of both OME and L-arg within the MET film matrix.  340 
 341 
Thermogravimetric analysis (TGA) 342 
The TGA results of blank films (aqueous and ethanolic) are shown in table 3 indicating the 343 
percentage loss with heating, attributed to residual water present within the film matrix. Due 344 
to PEG having hydrophilic characteristics, it was expected that the residual moisture content 345 
will increase for all films with increasing PEG 400 concentration. However, this was not the 346 
case except at higher concentrations (0.50 and 0.75 % w/w of PEG) where the % content 347 
increased. It also appears that the residual water was generally lower for films prepared using 348 
ethanolic gels than those from aqueous gels which is to be expected as there was less water in 349 
the original gel and ethanol generally allows faster drying than pure water on its own. In 350 
addition, the moisture content of less than 3% in all films was considered low enough to 351 
sustain drug stability during storage though this will need to be investigated with an 352 
accelerated stability study. 353 
 354 
Table 3: Weight loss observed for MET films cast from water, ethanol (10%) and ethanol 355 
(20%) gels containing different concentrations of PEG 400 (0, 0.25, 0.50 and 0.75 % w/w) 356 
MET blank Films 
Films Weight loss (%) 
MET, 0.00% PEG, aqueous 2.77  
MET, 0.25% PEG, aqueous 1.74 
MET, 0.50% PEG, aqueous 2.03 
MET, 0.75% PEG, aqueous 2.75  
MET, 0.00% PEG, 10% EtOH 2.26 
MET, 0.25% PEG, 10% EtOH 1.60 
MET, 0.50% PEG, 10% EtOH 2.12 
MET, 0.75% PEG, 10% EtOH 2.47  
MET, 0.00% PEG, 20% EtOH 2.64 
MET, 0.25% PEG, 20% EtOH 1.80 
MET, 0.50% PEG, 20% EtOH 1.99 
MET, 0.75% PEG, 20% EtOH 2.17  
 357 
 358 
 359 
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X-ray diffraction (XRD) 360 
To investigate the crystalline/ amorphous characteristics of all initial compounds and of the 361 
films, XRD was used. Amorphous compounds generally show very broad peaks, in 362 
comparison to the sharp peaks belonging to the crystalline form. XRD can also give 363 
information about the crystalline-amorphous ratios for the various starting materials and the 364 
formulated films (24). Figure 6 shows XRD diffractograms of pure MET and PEG 400, 365 
generally indicating the amorphous nature of MET and plasticiser.. Figures 6 also shows the 366 
diffractogram of blank plasticised MET films with broad peaks indicating amorphous 367 
characteristics as was observed in the pure polymers as well as the diffractograms of pure 368 
OME, L-arg and drug loaded film (20% EtOH 0.5%PEG 1:2 OME: L-arg). As can be seen, 369 
the results demonstrate that the drug loaded film was also amorphous suggesting possible 370 
molecular dispersion of the drug. This is interesting as it confirms the DSC results previously 371 
discussed and also the fact the MET together with L-arg were able to successfully maintain 372 
the stability of OME in amorphous form within the film matrix during formulation and 373 
storage prior to analysis. These results are interesting, however, it is well known that the 374 
amorphous forms are generally unstable and have the tendency to convert back to the 375 
amorphous forms. Therefore, further physical and chemical stability studies under controlled 376 
conditions of temperature and humidity (both normal and accelerated) are required over a 377 
longer period of time (over one month) for firm confirmation of its long term stability in the 378 
current physical state. 379 
 380 
Conclusions 381 
Due to the poor stability of OME in aqueous environment, L-arg was required in drug loaded 382 
films as a stabilizing agent. The most promising characteristics were observed in plasticised 383 
MET films (0.50 % PEG 400) prepared from ethanolic (20% v/v) gels and containing OME: 384 
L-arg ratio of 1:2. These characteristics include; transparency, ease of peeling and flexibility 385 
of the films for further investigation. It was also confirmed that OME originally loaded in 386 
crystalline form was molecularly dispersed (amorphous) within the MET film matrix. The 387 
MET films have potential for paediatric buccal administration and will be further functionally 388 
characterized to determine its in vitro cell culture, ex vivo and in vivo performance. 389 
 390 
 391 
 392 
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Legends to Figures 468 
Figure 1: Physical appearance (digital photograph) of films prepared using different 469 
polymers, i.e., sodium alginate (SA), metolose (MET), carrageenan (CA), hydroxypropyl 470 
methylcellulose (HPMC) and methylcellulose (MC). 471 
 472 
Figure 2: Tensile (tensile strength, percent elongation at break and elastic modulus) profiles 473 
of (a) MET films and (b) SA films containing different concentrations of PEG and cast from 474 
different solvent systems.  475 
 476 
Figure 3: (a) Degradation of OME in aqueous gel as evidenced by change in colour to red 477 
within 20 minutes of preparation; (b) films prepared from gels containing OME without L-478 
arg showing OME degradation and (c) films prepared from gels containing OME stabilized 479 
with L-arg. 480 
 481 
Figure 4: Scanning electron microscope images of (a) MET films cast from aqueous and 482 
ethanolic (10% and 20% v/v) gels containing different concentrations of PEG 400 (0% and 483 
0.50% w/w) and (b) SA films cast from aqueous and ethanolic (10% and 20% v/v) gels 484 
containing no PEG 400. 485 
 486 
Figure 5: DSC thermograms of (a) pure PEG and pure MET, (b) representative optimum 487 
blank, plasticized (0.50 % w/w PEG 400) MET films cast from ethanolic (20% v/v) gels and 488 
(c) pure L-arg, pure OME and drug loaded MET film prepared from ethanolic (20% v/v) gels 489 
containing OME: L-arg (1:2) and PEG 400 (0.50% w/w). 490 
 491 
Figure 6: XRD diffractograms for pure MET, pure PEG, pure OME, L-arg, blank MET 492 
films, and drug loaded MET films, showing amorphous drug distribution in the drug loaded 493 
films. 494 
 495 
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